Proteon Therapeutics Inc. said its experimental chronic kidney disease drug failed to meet the main goal in a late-stage study.

Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE in Europe, Canada and certain other international markets; OPKO Health to receive up to $282 million in upfront and milestone payments, plus tiered double-digit royalties.

People taking common heartburn medications known as proton pump inhibitors (PPIs) are at increased risk of new and severe kidney disease, according to a U.S. study. Among hundreds of thousands of patients in Department of Veterans Affairs (VA) databases, new users of PPIs without kidney disease were 30 percent more likely to develop chronic kidney […]

Keryx Biopharmaceuticals Inc. said its drug to treat iron deficiency anemia in chronic kidney disease patients not yet requiring dialysis met the goals of a late-stage clinical trial.

LONDON – Looking to strengthen its cardiovascular and metabolic offerings, London-based AstraZeneca (AZN) is snapping up Bay Area-based ZS Pharma (ZSPH) in a deal worth $2.7 billion in hopes of leveraging that company’s ion-trap technology treatments for hyperkalemia into a blockbuster drug. The deal, which will see AstraZeneca spend $90 per share for ZS Pharma, […]

The U.S. Food and Drug Administration approved Relypsa Inc’s drug to treat potentially fatal levels of potassium in patients with chronic kidney disease or heart problems. The drug, Veltassa, is designed to treat hyperkalemia, a chronic condition characterized by excessive potassium levels in the blood that could lead to dangerous changes in heart rhythm. Relypsa’s […]

People with high blood pressure who regularly take common painkillers known as non-steroidal anti-inflammatory drugs (NSAIDs) may increase their risk of developing chronic kidney disease, a study from Taiwan suggests. While some previous research has linked NSAIDs to impaired kidney function, the results have been mixed and often overlooked the effects on people with high […]